Mersha Chetty

Mersha Chetty

Auto-generated profile, based on publicly available information

Mersha Chetty

Sanofi, Reading, United Kingdom

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2024 in Infectious Diseases and Therapy
Verified
Journal Article
Open access
PDF file
AKAlexia Kieffer
Alexia Kieffer
MBMatthieu Beuvelet
Matthieu Beuvelet
GMGerald Moncayo
Gerald Moncayo
MCMersha Chetty
Mersha Chetty
ASAditya Sardesai
Aditya Sardesai
RHRichard Hudson
Richard Hudson
Introduction Respiratory syncytial virus (RSV) leads to significant morbidity in newborn infants in the United Kingdom (UK). Nirsevimab, a long-acting monoclonal antibody, received approval from the European Medicines Agency and has been licensed by the Medicines and Healthcare products Regulatory Agency for preventing RSV lower respiratory tract disease (LRTD) in neonates and infants during their first RSV season. The objective of this study was to assess the potential impact of nirsevimab on RSV-associated LRTDs, related costs, and loss of quality-adjusted life years (QALYs) in infants experiencing their first RSV season. Methods The impact of administering nirsevimab across all infant populations compared to palivizumab in the high-risk palivizumab-eligible population was assessed via a static decision-analytic model specified for a UK birth cohort experiencing their first RSV season. The RSV-related health events of interest included primary care (PC), accident and emergency (A&E) visits, hospitalizations [including hospitalizations alone and those resulting in intensive care unit (ICU) admissions], recurrent wheezing in infants who were previously hospitalized, and all-cause LRTD hospitalizations. Results Under the current standard of practice (SoP), RSV was estimated to result in 329,425 RSV LRTDs annually, including 24,381 hospitalizations and ICU admissions, representing £117.8 million (2024 GBP) in costs. Comparatively, universal immunization of all infants with nirsevimab could avoid 198,886 RSV LRTDs, including 16,657 hospitalizations and ICU admissions, resulting in savings of £77.2 million in RSV treatment costs. Considering the impact on all-cause LRTD of a universal immunization strategy, nirsevimab could be valued between £243 and £274, assuming willingness-to-pay (WTP) thresholds of £20,000 and £30,000 per QALY saved, respectively. Conclusions This analysis demonstrated that the health and economic burden of RSV would be substantially reduced in all infants experiencing their first RSV season in the UK (including term, preterm, and palivizumab-eligible infants) as a result of a universal immunization strategy with nirsevimab.

21 November 2025 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Closed access
MFMaria João Fonseca
Maria João Fonseca
SHSaskia Hagenaars
Saskia Hagenaars
MCMersha Chetty
Mersha Chetty
MBMathieu Bangert
Mathieu Bangert
LCLori Cirneanu
Lori Cirneanu
RHRichard Hudson
Richard Hudson
Background: A comprehensive analysis of the respiratory syncytial virus (RSV) burden in England is required. We estimated respiratory-related healthcare resource utilization (HCRU) and costs for infants experiencing RSV episodes. Methods: A birth cohort of all infants born between March 01, 2015, and February 28, 2017 (n = 449,591) was established using Clinical Practice Research Datalink-Hospital Episode Statistics. Case cohorts included infants with an episode of (1) RSV, (2) bronchiolitis, (3) any respiratory tract infection at <24 months and (4) RSV-predicted at <12 months. Treatments, procedures, clinical outcomes, respiratory-related HCRU and associated costs, and the patient pathway during the month before and 24 months following the index episode were described in case and comparative cohorts. Results: Among the 4813 infants in the RSV-coded case cohort (vs. comparative cohort), the mean number of respiratory-related healthcare visits was 5.1 (vs. 1.5), with the highest burden occurring in November and December, mostly in infants up to 12 months of age. Noninvasive and invasive ventilations were performed in 17% (vs. 0.47%) and 9% (vs.0.28%), respectively, 48% (vs. 38%) were prescribed antibiotics, and 0.44% (vs. 0.09%) died. Before and after the index episode, ~30% and ~75%, respectively, had another respiratory-related healthcare visit, with a mean cost of £4060 (vs. £242) per infant. Notably, minimal differences were observed across all outcomes between infants born before and during the RSV season. Conclusions: This study quantifies the significant impact of RSV infections in infants on the healthcare system. It highlights the need for effective preventive strategies for infants entering their first season.